TABLE 4.
Most common treatment regimens per myositis antibody.
| Auto-antibodies | Pulses CS | RTX | MMF | Azathioprine | Cyclophosphamide | IVIG | MTX |
| Anti-Jo-1 | 6 (30.0%) | 12 (60.0%) | 5 (25.0%) | 4 (20.0%) | 2 (10.0%) | 3 (15.0%) | 4 (20.0%) |
| Anti-MDA5 | 7 (50.0%) | 4 (28.6%) | 5 (35.7%) | 2 (14.3%) | 6 (42.9%) | 5 (35.7%) | 1 (7.1%) |
| Anti-PL-7 | 4 (36.4%) | 4 (36.4%) | 4 (36.4%) | 1 (9.1%) | 1 (9.1%) | 2 (18.2%) | 0 (0%) |
| Anti-PL-12 | 4 (36.4%) | 8 (72.3%) | 4 (36.4%) | 3 (27.3%) | 3 (27.3%) | 0 (0%) | 0 (0%) |
| Anti-OJ | 2 (22.2%) | 6 (54.5%) | 2 (22.2%) | 2 (22.2%) | 1 (11.1%) | 0 (0%) | 0 (0%) |
CS, corticosteroids; Jo-1, Histidyl-tRNA synthetase; IVIG, intravenous immune globulin; MDA5, melanoma differentiation-associated gene 5; MMF, mycophenolate mofetil; MTX, methotrexate; OJ, Isoleucyl-tRNA synthetase; PL-7, Threonyl-tRNA synthetase antibodies; PL-12, Alanyl-tRNA synthetase; RTX, rituximab.